ClinicalTrials.gg
Active, not recruitingNCT07146711Updated Aug 28, 2025

A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

A Phase 1 interventional study of Tamsulosin (0.4 mg/j) and Omnic Ocas®, in Healthy Adult Males Volunteers, sponsored by Berlin-Chemie AG Menarini Group. Active, not recruiting at 1 site in Armenia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Berlin-Chemie AG Menarini Group (part of Menarini Group) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.
  • Registered 5 months after the study started (first participant enrolled Mar 2025, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas®, Tamsulosin hydrochloride 0,4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), in healthy adult male subjects, at steady state.

Read the detailed description

The assessment of the bioequivalence of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), and Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands) after multiple dose administration in healthy male subjects at steady state.

02

Conditions studied

  • Healthy Adult Males Volunteers

Keywords

  • Bioequivalence
  • Tamsulosin
03

In context

Lead sponsor

Berlin-Chemie AG Menarini Group is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of understanding the form (ICF) and giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  2. Healthy male subjects aged 18 to 45 years inclusive, at the time of signing the ICF, able to tolerate venipuncture.
  3. Verified diagnosis of being "healthy" according to results of standard clinical, laboratory and instrumental methods of examination.
  4. Body weight ≥50 kg and ≤ 120 kg, between ≥18.5 and ≤30.0 kg/m2.
  5. Non-smokers (for at least 3 months).
  6. Subjects should be willing to remain abstinent (refrain from heterosexual intercourse) or use double barrier during participation in the study and for 30 days thereafter. Double-barrier contraceptive method: condom used together with spermicidal foam/gel/film/cream/suppository.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of allergies.
  2. Known or intolerance to tamsulosin and/or other alpha1 adreno-receptor antagonists and/or any of the study drugs.
  3. History of drug-induced angioedema.
  4. History, presence or necessity of glaucoma or cataract surgery.
  5. History or presence of acute or chronic diseases of cardiovascular (including arterial hypotension), bronchopulmonary, nervous, endocrine, reproductive systems (including ejaculation disorders), and also diseases of the gastrointestinal tract, liver (including hepatic insufficiency), urinary tract and kidneys (including renal insufficiency), blood, mental diseases; history of convulsive attacks.
  6. Acute infectious diseases (e.g. influenza, acute respiratory viral infections incl. COVID-19) less than 4 weeks before the first IMP administration.
  7. The presence of any other condition which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study.
  8. Surgery on the gastrointestinal tract (except appendectomy).
  9. Deviations from the normal parameters in clinical blood count analysis, biochemical blood analysis, urinalysis.
  10. History or presence of orthostatic hypotension or syncope.
  11. Systolic blood pressure measured in a sitting position, less than 100 mmHg or above 130 mmHg and/or diastolic blood pressure below 60 mmHg or above 89 mmHg.
  12. Heart rate less than 60 or more than 80 beats per minute.
  13. Deviation on the intervals and heart rate or ECG morphology.
  14. Positive test results for or or C or syphilis at screening.
  15. Positive test result for cotinine in the urine at screening or before randomisation.
  16. Positive screen for drugs or alcohol at screening or before randomisation.
  17. Known or suspected drug or alcohol abuse as judged by the Investigator.
  18. Alcohol consumption more than 10 units of alcohol a week (1 unit equivalent to 200 ml of dry wine or 50 ml of strong alcoholic drinks or 500 ml of beer) during the six months prior to the first administration of the IMP.
  19. Intake of xanthine containing substances (e.g., coffee, tea, chocolate, energy drinks, cola) as well as citrus fruits (grapefruit, grapefruit juice etc.) and cranberry (including juices, fruit drinks, etc.) within the last 72 hours before the IMP administration.
  20. Administration of medicines that have a significant effect on circulatory dynamics, liver function, etc. (barbiturates, omeprazol, cimetidin, NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, diuretics, etc.) less than 2 months or 5 half-lives (whatever is longer) before screening.
  21. The use of depot-forms of any drugs for 3 months or 5 half-lives (whatever is longer) before screening.
  22. Use of any prescribed or non-prescribed medication, herbal remedies, vitamins and minerals during the two weeks prior to the first administration of the IMP or longer (at least 5 elimination half-lives) if the medication has a long half-life.
  23. Mental, physical and other reasons that do not allow the subjects according to investigator's opinion to assess their behavior adequately, to follow correctly the requirements of the clinical study protocol and to assess the expected risks and possible discomfort.
  24. Dehydration (e.g. due to diarrhea, vomiting, or other causes) within the last 48 hours before the IMP administration.
  25. Subjects who have been on a special diet (for whatever reason, e.g. vegetarians or hypocaloric diet [less than 1000 cal/day]) during the 28 days prior to the first IMP administration and intention to maintain the diet during the study.
  26. Intention to perform excessive physical activities during the trial.
  27. Plasma donation within one month of screening or blood donation/blood loss >500 ml within 3 months before screening.
  28. Unwillingness or inability to follow the procedures and restrictions outlined in the protocol and the ICF.
  29. Participation in another clinical study within 3 months before the first IMP administration.
  30. Difficulty swallowing tablets or fasting or consuming standard meals.
  31. Any reason in the opinion of the Investigator, would prevent the subject from participating in the study.
  32. Scheduled to have vaccination during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets of Synthon Hispania SL, Spain

    Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets of Astellas Pharma Europe B.V., the Netherlands

    Drug: Tamsulosin (0.4 mg/j)

  • Active comparator
    Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets of Astellas Phar

    Multiple dose administration (7 days)

    Drug: Omnic Ocas®,

Interventions

  • DrugTamsulosin (0.4 mg/j)

    Drug page: Tamsulosin

    Multiple dose administration (7 days)

  • DrugOmnic Ocas®,

    Multiple dose administration (7 days)

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    Maximum plasma concentration at steady state

    Time frame: 7 days

  2. AUC(0-tau),ss

    Area under the curve at steady state

    Time frame: 7 days

  3. Ctau,ss

    Plasma concentration at the end of the dosing interval at steady state

    Time frame: 7 days

Secondary outcomes

  1. Cavg,ss

    Average concentration at steady state

    Time frame: 7 days

  2. Tmax,ss

    Time to maximum plasma concentration at steady state

    Time frame: 7 days

  3. Cmin,ss

    Minimum plasma concentration at steady state

    Time frame: 7 days

  4. Kel

    Terminal rate constant

    Time frame: 7 days

  5. PTF

    Peak-trough fluctuation over one dosing interval at steady state

    Time frame: 7 Days

  6. T 1/2

    Plasma half life

    Time frame: 7 days

  7. Swing

    (Cmax,ss-Cmin,ss)/ Cmin,ss

    Time frame: 7 days

Other outcomes

  1. Analysis of adverse events (AE)

    Number (%) of subjects with any AE

    Time frame: 31 days

  2. Analysis of adverse events (AE)

    Number (%) of subjects with treatment-related AEs

    Time frame: 31 days

  3. Analysis of adverse events (AE)

    Number (%) of subjects with any serious adverse events (SAE)

    Time frame: 31 days

  4. Analysis of adverse events (AE)

    Number (%) of subjects with treatment-related SAEs

    Time frame: 31 days

  5. Analysis of adverse events (AE)

    Number (%) of subjects discontinued from the study due to AEs

    Time frame: 31 days

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No — No publication in an ICMJE journal is planned

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Oct 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 28, 2025
StartActual
Mar 3, 2025
Primary completionEst.
Oct 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146711
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Mar 3, 2025
Primary completion
Oct 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Aug 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion